$2.23T
Total marketcap
$74.76B
Total volume
BTC 56.21%     ETH 9.01%
Dominance
Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated VRTX Stock

$468.42   0.349194%
Add to favorites
Market Cap
$118.89B
LOW - HIGH [24H]
$463.75 - $470.82
VOLUME [24H]
$1.18M
P/E Ratio
27.79
Earnings per share
$16.85
ISIN
US92532F1003
Price   Prediction

Vertex Pharmaceuticals Incorporated Price Chart

Sorry, that's all we've gotfor now...

Vertex Pharmaceuticals Incorporated VRTX Financial and Trading Overview

Vertex Pharmaceuticals Incorporated stock price 468.42 USD
Previous Close 451.63 USD
Open 455.65 USD
Bid 464.37 USD x 100
Ask 463.73 USD x 100
Day's Range 453.21 - 467.94 USD
52 Week Range 362.5 - 507.92 USD
Volume 1.82M USD
Avg. Volume 1.27M USD
Market Cap 118.47B USD
Beta (5Y Monthly) 0.31
PE Ratio (TTM) 27.702671
EPS (TTM) 16.85 USD
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date N/A
1y Target Est 548.69 USD

VRTX Valuation Measures

Enterprise Value 109.37B USD
Trailing P/E 27.702671
Forward P/E 21.740112
PEG Ratio (5 yr expected) 1.7
Price/Sales (ttm) 9.696663
Price/Book (mrq) 6.1275415
Enterprise Value/Revenue 8.951
Enterprise Value/EBITDA 21.956

Trading Information

Vertex Pharmaceuticals Incorporated Stock Price History

Beta (5Y Monthly) 0.31
52-Week Change 1.82%
S&P500 52-Week Change 24.48%
52 Week High 507.92 USD
52 Week Low 362.5 USD
50-Day Moving Average 438.06 USD
200-Day Moving Average 439.63 USD

VRTX Share Statistics

Avg. Volume (3 month) 1.27M USD
Avg. Daily Volume (10-Days) 1.43M USD
Shares Outstanding 253.81M
Float 253.02M
Short Ratio 3.46
% Held by Insiders 0.20%
% Held by Institutions 98.00%
Shares Short 4.49M
Short % of Float 2.00%
Short % of Shares Outstanding 1.77%

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor 2:1

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2025
Most Recent Quarter (mrq) March 31, 2026
Next Fiscal Year End December 31, 2026

Profitability

Profit Margin 35.50%
Operating Margin (ttm) 38.12%
Gross Margin 54.39%
EBITDA Margin 40.76%

Management Effectiveness

Return on Assets (ttm) 12.14%
Return on Equity (ttm) 24.19%

Income Statement

Revenue (ttm) 12.22B USD
Revenue Per Share (ttm) 47.91 USD
Quarterly Revenue Growth (yoy) 7.79%
Gross Profit (ttm) 6.65B USD
EBITDA 4.98B USD
Net Income Avi to Common (ttm) 4.34B USD
Diluted EPS (ttm) 16.85
Quarterly Earnings Growth (yoy) 59.59%

Balance Sheet

Total Cash (mrq) 7.25B USD
Total Cash Per Share (mrq) 28.55 USD
Total Debt (mrq) 1.99B USD
Total Debt/Equity (mrq) 10.26 USD
Current Ratio (mrq) 3.023
Book Value Per Share (mrq) 76.179

Cash Flow Statement

Operating Cash Flow (ttm) 4.24B USD
Levered Free Cash Flow (ttm) 2.78B USD

Profile of Vertex Pharmaceuticals Incorporated

Country United States
State MA
City Boston
Address 50 Northern Avenue
ZIP 02210
Phone 617 341 6100
Website https://www.vrtx.com
Industry Biotechnology
Sector(s) Healthcare
Full Time Employees 6400

Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Q&A For Vertex Pharmaceuticals Incorporated Stock

What is a current VRTX stock price?

Vertex Pharmaceuticals Incorporated VRTX stock price today per share is 468.42 USD.

How to purchase Vertex Pharmaceuticals Incorporated stock?

You can buy VRTX shares on the Tech Market Large exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Vertex Pharmaceuticals Incorporated?

The stock symbol or ticker of Vertex Pharmaceuticals Incorporated is VRTX.

Which industry does the Vertex Pharmaceuticals Incorporated company belong to?

The Vertex Pharmaceuticals Incorporated industry is Biotechnology.

How many shares does Vertex Pharmaceuticals Incorporated have in circulation?

The max supply of Vertex Pharmaceuticals Incorporated shares is 253.81M.

What is Vertex Pharmaceuticals Incorporated Price to Earnings Ratio (PE Ratio)?

Vertex Pharmaceuticals Incorporated PE Ratio is 27.79940600 now.

What was Vertex Pharmaceuticals Incorporated earnings per share over the trailing 12 months (TTM)?

Vertex Pharmaceuticals Incorporated EPS is 16.85 USD over the trailing 12 months.

Which sector does the Vertex Pharmaceuticals Incorporated company belong to?

The Vertex Pharmaceuticals Incorporated sector is Healthcare.

Vertex Pharmaceuticals Incorporated VRTX included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
{{ item.symbol }} {{ item.name }} {{ item.symbol }} {{ item.country.toUpperCase() }} {{ item.price }} {{ item.price_usd }}
{{ item.change_pct }}
{{ item.volume }} {{ item.volume_usd }} {{ item.low }} {{ item.low_usd }} {{ item.high }} {{ item.high_usd }} {{ item.components_count }} {{ item.volume }} {{ item.volume_usd }}
us US Tech Composite IXIC US 25587.04 USD
-2.21
13.85B USD 25513.26 USD 25882.57 USD 13.85B USD
us S&P 500 INDEX SPX US 7365.46 USD
-1.44
3.66B USD 7347.6 USD 7424.17 USD 3.66B USD
us S&P 500 (Yahoo.com) GSPC US 7365.46 USD
-1.44
3.66B USD 7347.6 USD 7424.17 USD 3.66B USD
us US100 NDX US 29347.27 USD
-3.29
1.5B USD 29276.98 USD 29748.72 USD 1.5B USD
us Dow Jones U.S. Biotechnology In DJUSBT US 3033.18 USD
+1.08
100.05M USD 3015.75 USD 3040.05 USD 100.05M USD
us US Tech-100 ESG JPY Index NDXESG07 US 3206.2 JPY 21.64 USD
-3.21
3197.77 JPY 21.59 USD 3247.62 JPY 21.92 USD
us US Tech-100 Total Return XNDX US 35811.68 USD
-3.29
35725.91 USD 36301.56 USD
us Stlmt ID US Tech 100 XQO US 16266.86 USD
-0.45
15738.2 USD 16639.8 USD
us US Tech Biotechnology Total Retu XNBI US 6750.7 USD
+0.85
6680.28 USD 6803.27 USD
us US Tech Biotechnology NBI US 6185.56 USD
+0.85
6121.03 USD 6233.73 USD
us US Tech Health Care IXHC US 1184.66 USD
+0.75
1174.72 USD 1192.68 USD
us US Tech-100 After Hours Indicato QIV US 29489.49 USD
-2.83
29365.41 USD 29492.37 USD
us US Tech US Smart Pharmaceuticals NQSSPH US 1926.14 USD
+1.34
1902.55 USD 1929.69 USD
us US Tech Global Select Market Com NQGS US 12546.99 USD
-2.24
12513.27 USD 12692.24 USD
us US Tech DM Ex Japan Large Mid Ca NQDMXJPLMAUD US 2100.38 AUD 1467.26 USD
<0.01
2100.38 AUD 1467.26 USD 2100.38 AUD 1467.26 USD
us US Tech-100 ESG Net Notional Tot NDXESG24 US 2340.14 EUR 2701.3 USD
-2.82
2332.97 EUR 2693.03 USD 2370.21 EUR 2736.02 USD
us US Tech-100 Notional Net Total R XNDXNNR US 34179.22 USD
-3.29
34097.35 USD 34646.76 USD
us US Tech-100 Equal Weighted NDXE US 10041.73 USD
-2.15
10017.5 USD 10127.37 USD
us US Tech-100 Micro Index XND US 293.47 USD
-3.29
292.77 USD 297.49 USD
us Stlmt ID US Tech Biotechnology NBX US 3995.9 USD
-4.37
4555.41 USD 4917.8 USD
Select currency